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ABSTRACT
Objective: The purpose of this study was to determine if treatment of pregnant women with Chla-
mydia trachomatis infection would lower the incidence of preterm delivery and/or low birth weight.
Methods: Pregnant women between the 23rd and 29th weeks of gestation were randomized in
double-blind fashion to receive either erythromycin 333 mg three times daily or an identical placebo.
The trial continued until the end of the 35th week of gestation.
Results: When the results were examined without regard to study site, erythromycin had little
impact on reducing low birth weight (8% vs. 11%, P 0.4) or preterm delivery (13% vs. 15%, P
0.7). At the sites with high persistence of C. trachomatis in the placebo-treated women, low birth
weight infants occurred in 9 (8%) of 114 erythromycin-treated and 18 (17%) of 105 placebo-treated
women (P 0.04) and delivery <37 weeks occurred in 15 (13%) of 115 erythromycin-treated and
18 (17%) of 105 placebo-treated women (P 0.4).
Conclusions: The results of this trial suggest that the risk of low birth weight can be decreased by
giving erythromycin to some women with C. trachomatis. Due to the high clearance rate of C.
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he prevalence of Chlamydia trachomatis varies
widely depending upon the population, with
5-15% of pregnant women being infected. 1-3 Dur-
ing pregnancy, C. trachomatis is isolated 4-8 times
more frequently than Neisseria gonorrhoeae, z,4,s C.
trachomatis is particularly common among adoles-
cents and individuals from low socioeconomic
groups,6,7 and it has been associated with adverse
pregnancy outcomes in most, but not all, re-
ports. 1,z,4,6,8,9
Treatment of C. trachomatis in pregnancy has
been associated with improved pregnancy out-
come. In one study, the rate of abnormal pregnancy
outcome was significantly lower in women with C.
trachomatis who were treated with erythromycin
over a 20 month study period compared to the rate
in untreated women examined during the 16
month interval preceding the study period.1 Fur-
thermore, women infected with C. trachomatis who
were treated had the same frequency of abnormal
outcome as did uninfected women.1 In another
study, fewer abnormal pregnancy outcomes oc-
curred among C. trachomatis-positivc women who
were effectively treated than among those who re-
mained culture positive.1 Neither of these studies
used a randomized or blinded treatment protocol
nor did they account for other bacteria or obstetri-
cal factors associated with poor pregnancy out-
come.
We report the results of a randomized placebo-
controlled double-blinded trial of erythromycin
treatment of C. trachomatis infection during preg-
nancy. Our study was able to adjust for the influ-
ence of demographic, sexual, and obstetrical factors
as well as the presence of other potentially patho-
genic organisms isolated from the lower genital
tract.
SUBJECTS AND METHODS
Study Design
As part of the Vaginal Infection and Prematurity
(VIP) Study, pregnant women were enrolled from
seven institutions utilizing six antepartum clinics
(Harlem Hospital, New York, NY; Columbia Uni-
versity, New York, NY; Louisiana State University
and Tulane University, New Orleans; University of
Oklahoma, Oklahoma City; University of Texas
Health Science Center, San Antonio; and Univer-
sity of Washington, Seattle). A uniform protocol
had been agreed upon, including a standardized
questionnaire and common laboratory methods.
Women seeking prenatal care between the 23rd
and 26th completed weeks of pregnancy were
screened for eligibility to enter the observational
phase of the study. Women were eligible if they
were ->16 years old, were free of medical compli-
cations related to premature delivery, and were not
taking selected medications. Details of inclusion
and exclusion criteria have been published previ-
ously, lz,3 Research personnel obtained demo-
graphic, obstetric, sexual, contraceptive, and drug
use history on standardized coded forms; per-
formed a standardized physical and pelvic exami-
nation; and collected urogenital cultures in a stan-
dard manner. At delivery the medical records of the
mother and infants were reviewed and information
on intervening therapy, including non-trial antibi-
otic use, was abstracted.
Women identified as colonized with Ureaplasma
urealyticum, group B streptococci, and/or C. tracho-
matis were considered for randomization into the
clinical trial. The clinical trial results for women
positive for U. urealyticum but negative for group B
streptococci and C. trachomatis have been pub-
lished, as have the results for women with group
B streptococci, ae
Collection of Urogenital Specimens
Following the insertion of sterile cotton swabs into
the endocervix to obtain specimens for Gram’s
stain, and for N. gonorrhoeae and group B strepto-
coccal culture, a sterile Dacron swab with a plastic
shaft was then inserted within the endocervical ca-
nal and rotated for several seconds to obtain a
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specimen for C. trachomatis culture. The swab tip
was broken off in a vial containing 1.5 ml of phos-
phate buffered 0.2 M sucrose solution. The speci-
men was maintained at refrigerator temperature
until it reached the laboratory later that day. De-
tails of specimen collection methods for the other
microorganisms have been published. 13
Culture Methods
The protocol for C. trachomatis culture followed by
all centers was as follows: the swab was removed
from the transport vial and a sample of the carrier
media was inoculated onto McCoy cell monolayers
grown in one dram shell vials at all centers as de-
scribed 14 except for the University of Washington,
which used 96-well microtiter plates.s At least two
monolayers were inoculated for each specimen. Vi-
als or plates were then centrifuged for h at 1,000-
2,500 g. After replacement of the inoculum with
cell culture media, vials and/or plates were incu-
bated at 35C for 48-68 h. One coverslip or one
well was then stained with fluorescein isothiocya-
nate-conjugated C. trachomatis-specific monoclonal
antibody and read with a fluorescent microscope.
For positive specimens, C. trachomatis inclusions in
10-20 random microscopic fields were counted to
semiquantitate the number of viable organisms in
each specimen. For negative specimens, the cells
were scraped off the bottom of the second vial or
well using a pipette tip and inoculated onto fresh
monolayers. The culture procedure was then re-
peated. A specimen was considered negative only
if inclusions were not observed in monolayers in-
oculated with the passed specimen.
Clinical Trial Methods
Women from whom C. trachomatis was recovered in
the observational study were eligible to participate
in the clinical trial. However, women receiving an-
tibiotics since the screening examination, who
were allergic to erythromycin or receiving theoph-
ylline were ineligible. Women with positive
screening cultures for N. gonorrhoeae or > l0s micro-
organisms/ml of urine were treated and thus ineli-
gible for the trial.
Eligible women who agreed to participate in the
clinical trial entered a week placebo run-in.6
Those who took less than two-thirds of the allotted
placebo pills during the run-in, who did not return
to the clinic or refused further participation were
not randomized. Patients who successfully com-
pleted the run-in, had none of the exclusion crite-
ria, and were <30 weeks gestation were randomized
as described previously.3 The randomization
scheme stratified women by study site and micro-
organism combination to allow for subgroup-
specific analyses. Participants were treated with ei-
ther erythromycin base (333 mg) or identical-
appearing placebo tablets 3 times daily from blister
packs containing 21 pills each. The erythromycin
and placebo were supplied by the Upjohn Com-
pany (Kalamazoo, MI).
As a result of concerns that a daily dose of 2 g of
erythromycin would be poorly tolerated over 6
weeks, the lower g dose was chosen. Earlier re-
ports suggested that a g daily dose for 6 weeks in
the third trimester decreased the rate of low birth
weight infants among women colonized with geni-
tal mycoplasmas.7 Previous experience of the in-
vestigators suggested that 500 mg erythromycin
taken twice daily for 14 days effectively treated
endocervical C. trachomatis in pregnant women
(Martin and Eschenbach, unpublished data).
Treatment of partners was recommended, but
therapy was given to the study participants until
the completion of the 35th week of pregnancy to
reduce the likelihood of reinfection.
Women were evaluated at each regular antenatal
visit, at which time compliance (by pill count) and
side effects were recorded by a research nurse us-
ing a standardized questionnaire, used blister packs
were collected, and additional medication was sup-
plied.
Quality Control/Drug Efficacy Issues
Repeat cultures were obtained 2-4 weeks after en-
rollment from the first 100 women enrolled into the
clinical trial at each study site. In addition, a ran-
dom sample of 12% of all study participants was
selected to have repeat cultures (6% at 31-33
weeks and 6% at 34-36 weeks gestation). Repeat
cultures also were obtained from women admitted
for pregnancy complications at <37 weeks gestation
(premature labor, rupture of membranes) and from
all women admitted to the hospital in term labor
during weekday daytime hours.
Two methods were used for quality control of (7.
trachomatis cultures. Each study site in turn sent 5
"unknowns" that included both positive and nega-
tive specimens to the other centers. In addition, a
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random sample of women had duplicate C. tracho-
matis specimens obtained and submitted to the
laboratories for culture. Different study numbers
were assigned to blind laboratory personnel to the
duplicate specimens.
Definitions
Gestational age at study entry was estimated from
the last menstrual period, results of the first pelvic
examination, onset of fetal heart tone, and ultra-
sound data when available. Gestational age at de-
livery was calculated from the entry estimate and
the time to delivery. All women had pertinent
pregnancy, labor, and delivery information col-
lected including the use of non-trial antibiotics.
Premature rupture of membranes was defined as
membrane rupture before the onset of regular uter-
ine contractions.
Antibiotics considered effective against C. tra-
chomatis included erythromycin, ampicillin, tetracy-
cline, oral sulfa preparations, and penicillin VK.
Antibiotics considered ineffective included metro-
nidazole, cephalosporins, nitrofurantoin, penicillins
other than VK or ampicillin, and vaginal sulfa
cream.
Post-Delivery
Trial participants with C trachomatis were retreated
with doxycycline, tetracycline, or erythromycin im-
mediately postpartum, regardless of which trial
medication they received. Infants were either
treated empirically after delivery or were followed,
cultured at their first postnatal visit, and treated
with antibiotics if indicated.
Statistical Analysis
Categorical variables were compared using the chi-
square test or Fisher’s exact test. 18 Significance was
defined as a two-tailed P < 0.05. All calculations
were done using SAS with the exception of logistic
regression analyses, which were done using BMDP
procedures. 19
RESULTS
Between November 1, 1984, and March 31, 1989,
13,914 women were enrolled into the VIP Study, of
whom 13,750 (99%) had C. trachomatis results avail-
able. C. trachomatis was isolated from 1,239 (9.0%)
women, 204 of whom were ineligible for the trial
due to N. gonorrhoeae infection (n 59), asymptom-
atic bacteriuria (n 60), or other exclusion criteria.
We were able to contact 933 of the 1,035 eligible
women. Of those contacted, 218 women (23%) did
not keep their enrollment appointment, 121 (13%)
refused to participate, and 594 women were en-
tered into the placebo run-in. The 180 women who
did not comply with the run-in were not random-
ized, leaving 414 women who were randomized to
receive either erythromycin (205) or placebo (209).
After starting medication, 25 erythromycin-treated
and 23 placebo-treated women withdrew from the
trial but were included in the intent-to-treat analy-
sis.
The two groups were compared with respect to
demographic, behavioral, and obstetrical character-
istics (Table 1). No significant differences were
seen in baseline characteristics between the groups
(Table 1). Additional factors that did not differ be-
tween groups included living arrangement;
method/source of medical payment; work during
pregnancy; number of sexual partners during preg-
nancy, in the last year, and lifetime; frequency of
intercourse; prior genital or kidney infection; his-
tory of a cone biopsy; difficulty becoming pregnant;
hospitalization during pregnancy; general health;
illicit drug use; mean height and weight; past chla-
mydial or gonococcal infection or present genital
infection (group B streptococci, U. urealyticum,
Trichomonas vaginalis, bacterial vaginosis, or endo-
cervical mucopus).
The pregnancy outcomes of women entered
into the trial are summarized in Table 2. The mean
birth weight of infants was similar in the two
groups as was the distribution of birth weights.
Birth weight <2,500 g occurred in 8% of erythro-
mycin-treated and 11% of placebo-treated women
(P 0.4) Additionally, there were no differences in
the distribution of gestational age, gestational age
at the time of premature rupture of membranes
(PROM), or the total proportion of women experi-
encing PROM. The numbers of stillbirths and neo-
natal deaths were low in both groups. Thus, when
data from all study sites were combined, there was
no statistically significant impact of erythromycin
on pregnancy outcome, although there were fewer
low birth weight infants, fewer deliveries <37
weeks gestation, and fewer instances of PROM in
the erythromycin compared to the placebo group.
Compliance data were available for 199 of the
205 women in the erythromycin group and 206 of
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TABLE I. Descriptive characteristics of patients
with C. trachomatis randomized to receive either
erythromycin or placebo
Erythromycin Placebo
(n 205) (n 209)
Mean age + S.D. (years) 21.5 + 4.2 21. + 4.3
Mean gravidity + S.D. 2.0 + 1.2 1.9 + 1.2
Mean gestational age when 24.5 + I. 24.5 + I.
screened + S.D. (weeks)
Mean gestational age when 29.4 + 1.8 29.4 + 1.5
randomized + S.D. (weeks)
Ethnicity
White, Asian, and Native 34 (I 7%) 33 (16%)
American
Black 126 (61%) 123 (59%)
New York Hispanic 34 (17%) 47 (22%)
Non-New York Hispanic II (5%) 6 (3%)
Marital status
Married 59 (29%) 48 (23%)
Separated/divorced/widowed 18 (9%) 21 (10%)
Never married 127 (62%) 140 (67%)
Education (years)
<12 90 (44%) 97 (47%)
12 84 (41%) 73 (35%)
>12 30 (I 5%) 38 (I 8%)
Smoked cigarettes during the 50 (24%) 48 (23%)
pregnancy
Used alcohol during the 35 (I 7%) 37 (18%)
pregnancy
Prior low birth weight delivery
Yes 46 (22%) 52 (25%)
No 70 (34%) 55 (26%)
First pregnancy 89 (43%) 102 (49%)
Study site
Harlem Hospital 6 (3%) 9 (4%)
Columbia University 54 (26%) 59 (28%)
University of Washington 6 (3%) 7 (3%)
University of Oklahoma 29 (14%) 33 (16%)
University of Texas 10 (5%) 3 (1%)
Louisiana State University/ 100 (49%) 98 (47%)
Tulane University
alncluded patients who delivered an infant weighing <2,500 with a prior
pregnancy.
the 209 women in the placebo group. Twenty-
three percent of the 199 erythromycin-treated
women took less than two-thirds of their pills com-
pared to 16% of the 206 placebo-treated women (P
0.053). Nausea was the only side effect reported
significantly more often among women in the
erythromycin group (33%) compared to the placebo
group (21%) (P 0.005). Appetite loss was also
more frequent in the erythromycin than the pla-
cebo group (21% vs. 14%, P 0.08). Overall, 55% of
women taking erythromycin experienced at least
one side effect compared to 43% ofwomen on pla-
cebo (P 0.01). The effect of erythromycin on low
birth weight and preterm delivery was stratified by
TABLE 2. Effect of erythromycin treatment on
pregnancy outcome in patients with C. trachomatis
for the total group in an intent-to-treat analysis
Outcome/total
Erythromycin Placebo
(n 205) (n 209)
Mean birth weight + S.D. (g) 3,192 + 524 3,146 + 552
Low birth weight at delivery (g)
<1,500 0/201 2/199 (I %)
1,500-2,499 17/201 (8%) 20/199 (I 0%)
Total <2,500 17/201 (8%) 22/199 (I I%)
Gestational age at delivery (weeks)
<32 1/202 (0.5%) 1/203 (0.5%)
32-36 26/202 (I 3%) 29/203 (I 4%)
Total <37 27/202 (I 3%) 30/203 (I 5%)
Premature rupture of membranes (weeks)
<37 5/196 (3%) 7/193 (4%)
-->37 16/196 (8%) 18/193 (9%)
Total PROM 21/196 (I I%) 25/193 (I 3%)
Stillbirth 2/202 (1%) 1/203 (0.5%)
Neonatal death 1/202 (0.5%) 0/203
aThe difference between the number of women enrolled in each arm of
the treatment trial and the numbers assessed for each outcome reflect
the numbers of women for whom data could not be obtained.
compliance with no apparent effect on pregnancy
outcome.
Endocervical C. trachomatis cultures obtained
mid-study, while women were still receiving the
study drug, remained positive in 20% of erythro-
mycin-treated and 63% of placebo-treated women
(P < 0.001). C. trachomatis was recovered from 8
(14%) of 56 erythromycin-treated women who took
two-thirds or more of their pills compared to 7
(33%) of 19 women taking less than two-thirds of
their erythromycin (P 0.03).
Because of the unexpectedly high clearance of
C. trachomatis in the placebo group (37%), the data
were analyzed separately by study site (Table 3).
The interim recovery rates were low (24-25%) in
the placebo group at the New York and Oklahoma
sites as opposed to the New Orleans and Seattle
sites, where 89% and 83% of placebo-treated
women continued to have positive cultures. Only
one woman at San Antonio had repeat culture data.
In an attempt to explain these results, we first
examined the repeatability of culture results from
the quality control data. Recovery rates of C. tra-
chomatis from quality control specimens were simi-
lar at the various sites. Overall, laboratories cor-
rectly identified 70 of 75 positive and 84 of 85
negative C. trachomatis quality control specimens.
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TABLE 3. Bacteriologic effect of erythromycin
treatment measured by interim endocervical
C. trachomatis cultures
No. C. trachomatis positive/No, treated
Erythromycin Placebo P
New Orleans 10/39 (25%) 39/44 (89%) <0.001
Seattle 0/4 5/6 (83%) 0.048
San Antonio 0/I 0/0
New York I/21 (5%) 4/I 9 (24%) 0.17
Oklahoma 5/13 (38%) 3/12 (25%) 0.67
aThe two New Orleans sites and the two New York ,ites utilized the
same laboratories and the data were combined.
The results of blinded split specimens were also in
agreement. The proportion of samples for which
both specimens were positive among the total with
at least one positive specimen were: Louisiana
State University/Tulane, 24/29 (83%); Columbia
University/Harlem, 16/22 (73%); University of
Oklahoma, 3/10 (30%); University of Washington,
0/1 (0%); and University of Texas 1/1 (100%).
We next examined data on the use of antibiotics
prescribed outside of the clinical trial as a possible
explanation for the high clearance rate in the pla-
cebo group. Significantly more use of non-trial an-
tibiotics effective against C. trachomatis occurred in
the placebo than the erythromycin group (22 vs. 8
women, P < 0.01). Harlem, Columbia, and Oklaho-
ma showed a greater use of antibiotics in the pla-
cebo than the erythromycin group (33.3% vs. 0.0%,
17.0% vs. 1.9%, 18.8% vs. 3.5%, respectively). New
Orleans had roughly similar rates in the two groups
(5.6% vs. 2.8%), while San Antonio showed a
greater use of non-trial antibiotics in the erythro-
mycin group (0 vs. 20.0%). The number of women
receiving effective antibiotics did not explain all of
the differences in C. trachomatis positively among
placebo-treated women.
The trial outcome data were then stratified into
two groups: data from study sites with low vs. high
C. trachomatis clearance in the placebo group. In the
sites with low clearance (New Orleans, Seattle, and
San Antonio), low birth weight infants occurred in
9 of 114 erythromycin-treated and 18 of 105 pla-
cebo-treated women (P 0.04; Table 4) and deliv-
ery <37 weeks occurred in 15 of the 115 erythro-
mycin and 18 of the 105 placebo group (P 0.4). In
the sites with high clearance (New York and Okla-
homa), low birth weight occurred in 8 of 87 eryth-
romycin-treated and 4 of 94 placebo-treated
women (P 0.18) and delivery <37 weeks occurred
in 12 of 87 erythromycin-treated and 12 of 98 pla-
cebo-treated women (P 0.75).
DISCUSSION
In the intent-to-treat analyses, there were no ap-
parent beneficial effects of erythromycin treatment
on low birth weight, preterm delivery, PROM, or
perinatal mortality. However, when the analysis
took into account the clearance of C. trachomatis in
the placebo group, erythromycin was associated
with a 50% reduction in the rate of low birth weight
in the centers with low clearance.
The higher rate of low birth weight in the pla-
cebo group in these sites is consistent with the
increased rate of low birth weight observed among
untreated women with C. trachomatis in other stud-
ies. 1,z,4,5,1 The proportion of infants with low birth
weight in the erythromycin group (8%) was consis-
tent with that for C. trachomatis-negative women in
the observational component of the VIP Study
(7.6%), and the proportion of low birth weight in-
fants in the placebo group (11%) was similar to that
among C. trachomatis-positive women in the VIP
Study (10.6%) who were not entered into the trial.
There were at least three significant problems
that interfered with our ability to detect an overall
effect of erythromycin on pregnancy outcome.
First, the trial included only 414 women, so the
ability to detect small but potentially important dif-
ferences between the erythromycin and placebo
groups was limited. Second, approximately 20% of
women receiving erythromycin remained C. tracho-
marls positive as determined from the random
sample who were recultured. Third, at three study
sites which contributed 46% of the cases to the
trial, high clearance of C. trachomatis occurred in the
placebo group.
The 20% failure rate of erythromycin in our
study suggests the g dose is less than optimal,
possibly due to the 40% increase in blood and ex-
tracellular volume in pregnancy acting to reduce
serum and tissue drug levels. While some investi-
gators have reported cure rates in pregnancy of98%
with 1,500 mg of amoxicillin daily for 7 days,z and
95% with 1,000 mg of clindamycin daily for 14
days,zl cure rates with erythromycin seem to be
more variable, perhaps related to gastrointestinal
tolerance and, in turn, to non-compliance,z C. tra-
chomatis cure rates after erythromycin have ranged
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TABLE 4. Stratification of trial outcome by treatment and study center
Study site stratified by
C. trachomatis clearance
in the placebo group
Birth weight <2,500 g Delivery at <37 weeks
Erythromycin Placebo Erythromycin Placebo
(n 201) (n 199) (n 202) (n 203)
High clearance
New York-Harlem I/6 (I 7%) 0/9 (0%) I/6 (I 7%) I/9 (I I%)
New York-Columbia 5/52 (10%) 2/53 (4%) 8/52 (I 5%) 6/57 (I I%)
Oklahoma City 2/29 (7%) 2/32 (6%) 3/29 (10%) 5/32 (I 6%)
Total 8/87 (9%) 4/94 (4%) 12/87 (I 4%) 12/98 (I 2%)
Low clearance
Seattle I/6 (I 7%) 0/7 (0%) 3/6 (50%) I/7 (I 4%)
San Antonio 0/10 (0%) 0/3 (0%) 1/10 (I 0%) 0/3 (0%)
New Orleans 8/98 (8%) 18/95 (I 9%) 1/99 (I I%) 17/95 (I 8%)
Total 9/I 14 (8%) 18/105 (I 7%) 15/I 15 (I 3%) 18/105 (I 7%)
from 92 to 95% with 1,600-2,000 mg daily doses for
7 daysz,zz to 76-88% with 1,000-2,000 mg daily
doses for 7-14 days. 11,zl Direct comparisons of
1,000 vs. 2,000 mg daily doses of erythromycin
have not been performed during pregnancy, but in
non-pregnant women, one study has suggested that
the 1,000 mg dose appears to be less effective than
the 2,000 mg daily dose. C. trachomatis was recov-
ered after therapy in 27% of 45 non-pregnant
women given 1,000 mg and 10% of 31 non-
pregnant women given 2,000 mg.z3 The low recov-
ery rate in the placebo group was unexpected since
other studies have shown that C. trachomatis per-
sists in 85-90% of untreated non-pregnantz-3,z4 and
71-75% of untreated pregnant women,z
The effect of treating C. trachomatis has been
reported in two studies. Ryan et al.1 compared
data on the pregnancy outcome of C. trachomatis-
infected women treated with 2 g of erythromycin
for 7 days with historical data on untreated women
with C. trachomatis cared for in the previous 16
months in the same antenatal clinic. Treatment
with erythromycin was associated with a 50% re-
duction of low birth weight, a 45% reduction of
PROM, and a 400% increase in newborn survival.1
Cohen et al.1 reported the pregnancy outcome of
women who were initially C. trachomatis positive
and then underwent multiple repeat cultures after
standard erythromycin therapy to detect treatment
failures and reinfection. Low birth weight, PROM,
and preterm delivery were more common in the
women who remained positive than in the women
who became C. trachomatis negative.1 Neither of
these studies employed a randomized trial design.
What conclusions may be drawn from the stud-
ies of C. trachomatis and pregnancy outcome to
date? Data from our observational study suggest an
impact of untreated C. trachomatis on low birth
weight, preterm delivery, and preterm PROM. Re-
sults of site-specific analyses from our clinical trial
together with the results of Ryan et al.1 and Cohen
et al. suggest that the risk of low birth weight in
C. trachomatis-positive women can be decreased by
erythromycin treatment.
Even in the absence of incontrovertible evi-
dence of a role of C. trachomatis in abnormal preg-
nancy outcome, there is a strong rationale for the
antepartum diagnosis and treatment of Chlamydia.
First, treatment prevents transmission of C. tracho-
matis to the infant at delivery. The 15-20% rate of
chlamydial conjunctivitis and chlamydial pneumo-
niazs appears to be reduced by 90% when the
mother is treated,z,zz Second, treatment reduces
the spread to sexual partners. Third, treatment can
prevent fallopian tube damage and possible future
tubal infertility among women who otherwise
would be chronically infected or develop salpingitis
postpartum,z6
Therefore, antepartum screening and treatment
of C. trachomatis are recommended by the Centers
for Disease Control (CDC).z7 Although treatment
at 36 weeks of pregnancy would prevent vertical
transmission to the 90% of infants born beyond this
time,z,zz screening and treatment late in preg-
nancy would not be expected to prevent premature
delivery. Treatment in the mid-trimester could
both potentially reduce premature delivery rates
and protect the infant from vertical transmission. In
our opinion, these considerations tip the balance in
favor of mid-trimester as the optimal time to treat
C. trachomatis as opposed to the later time recom-
mended by the CDC.z7
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